OS Therapies Q3 net loss $2.9M; Phase 2b osteosarcoma data due Dec 2024

OS Therapies Inc

2024-Q3 EPS reported -$0.64

Net operating loss $2.875M in Q3 2024 vs $2.006M in Q3 2023; EPS -$0.18 vs -$0.38.
Completed dosing all 41 patients in Phase 2b trial of OST-HER2 in resected recurrent osteosarcoma.
Topline Phase 2b data expected December 2024; seeking FDA Breakthrough Therapy designation.
Company completed IPO in Q3 2024; pre-revenue with future revenue expected from priority review voucher.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.